Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment‐resistant schizoaffective disorder
Bipolar Disorders · 2024
DOI: 10.1111/bdi.13385 ↗Kurz gefasst
Fallbericht in der Zeitschrift Bipolar Disorders, 2024. Verfasst von Jin-Jie Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing An…. Hauptthemen laut MEDLINE: Clozapine, Antipsychotic Agents, Bipolar Disorder, Psychotic Disorders. Die Arbeit nennt 5 Literaturangaben. Gefördert von: Beijing Municipal Administration of Hospitals Incubating Program, the Scientific Research Fund of Beijing Anding Hospital.
Abstract (Originalsprache)
We report the case of a Chinese male with schizoaffective disorder, an active smoker and a nonresponder to clozapine (600 mg daily). Therapeutic clozapine monitoring was analyzed, revealing a low concentration‐dose ratio. A pharmacogenetic test showed that the patient had the CYP1A2*1F/*1F genotype, indicating an ultra‐rapid clozapine metabolizer. In combination with fluvoxamine, a CYP1A2 enzyme inhibitor, clozapine plasma concentrations approached the reference range and achieved clinical improvement. This case demonstrates how pharmacogenetics can help understand the value of therapeutic drug monitoring to enhance the treatment of refractory schizoaffective disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China.
- Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing, China.
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA.
- Mental Health Service Line, Joseph Maxwell Cleland Atlanta VA Medical Center, Decatur, Georgia, USA.
ORCID-Profile: Jin-Jie Xu
Förderung
- Beijing Municipal Administration of Hospitals Incubating Program
- the Scientific Research Fund of Beijing Anding Hospital
Zitieren
APA
Xu, J. J., Xiao, C., Pan, Y., Tang, Y. L., Wang, M., Li, S., Xie, G., Du, J., Ren, Y., & Wang, W. (2024). Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment‐resistant schizoaffective disorder. Bipolar Disorders. https://doi.org/10.1111/bdi.13385
Vancouver
Xu JJ, Xiao C, Pan Y, Tang YL, Wang M, Li S, et al. Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment‐resistant schizoaffective disorder. Bipolar Disorders. 2024. doi:10.1111/bdi.13385
BibTeX
@article{Xu2024,
author = {Xu, Jin-Jie and Xiao, Chunfeng and Pan, Yanli and Tang, Yi-Lang and Wang, Mingwan and Li, Sheng and Xie, Gaoming and Du, Jing and Ren, Yanping and Wang, Wei},
title = {Utilizing plasma drug levels and genetic testing to achieve optimal treatment response in a patient with treatment‐resistant schizoaffective disorder},
journal = {Bipolar Disorders},
year = {2024},
doi = {10.1111/bdi.13385}
}
EUVIMED